MAGEA6
Melanoma-associated antigen 6
Also known as: CT1.6, MAGA6_HUMAN, MAGE-3b, MAGE3B, MAGE6
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P43360
- Gene
- MAGEA6
- Ensembl
- ENSG00000197172
- Chromosome
- X
- Canonical length
- 314 aa
- Protein class
- Cancer-related genes, Predicted intracellular proteins
OverviewNCBI Gene
This gene is a member of the MAGEA gene family. The members of this family encode proteins with 50 to 80% sequence identity to each other. The promoters and first exons of the MAGEA genes show considerable variability, suggesting that the existence of this gene family enables the same function to be expressed under different transcriptional controls. The MAGEA genes are clustered at chromosomal location Xq28. They have been implicated in some hereditary disorders, such as dyskeratosis congenita. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
314 residues, UniProt reviewed canonical sequence.
>P43360|MAGEA6
1 MPLEQRSQHC KPEEGLEARG EALGLVGAQA PATEEQEAAS SSSTLVEVTL GEVPAAESPD
61 PPQSPQGASS LPTTMNYPLW SQSYEDSSNQ EEEGPSTFPD LESEFQAALS RKVAKLVHFL
121 LLKYRAREPV TKAEMLGSVV GNWQYFFPVI FSKASDSLQL VFGIELMEVD PIGHVYIFAT
181 CLGLSYDGLL GDNQIMPKTG FLIIILAIIA KEGDCAPEEK IWEELSVLEV FEGREDSIFG
241 DPKKLLTQYF VQENYLEYRQ VPGSDPACYE FLWGPRALIE TSYVKVLHHM VKISGGPRIS
301 YPLLHEWALR EGEELocalizationUniProt · AlphaFold · HPA
Whether an antibody against MAGEA6 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.43
- Highest tissue expression
- 7 nTPM
Expression across tissuesHPA
Tissue
- testis: 7 nTPM
- endometrium: 0.3 nTPM
- adipose tissue: 0.2 nTPM
- cerebral cortex: 0.1 nTPM
- placenta: 0.1 nTPM
- spleen: 0.1 nTPM
Single-cell type
- early primary spermatocytes: 44 nCPM
- differentiating spermatogonia: 36 nCPM
- undifferentiated spermatogonia: 31 nCPM
- late primary spermatocytes: 2.1 nCPM
- gastric progenitor cells: 1.3 nCPM
- late spermatids: 1.2 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- cerebral cortex: 0.1 nTPM
- amygdala: 0 nTPM
- basal ganglia: 0 nTPM
- cerebellum: 0 nTPM
- choroid plexus: 0 nTPM
- hippocampal formation: 0 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about MAGEA6.
Disease | ImmuneIEDB
Conditions an epitope on MAGEA6 was assayed in.
- melanoma T cell
- skin melanoma T cell
- intrahepatic cholangiocarcinoma T cell
- acral lentiginous melanoma T cell
ReferencesPubMed · IEDB
Publications for MAGEA6 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
2 publications
- Diagnostic performance of anti-MAGEA family protein autoantibodies in esophageal squamous cell carcinoma.
2023 · Int Immunopharmacol · RCR 0.5 · 4 citations - Serum cancer testis antigen MAGEA3-IgG serves as a diagnostic biomarker in lung adenocarcinoma.
2026 · Clin Transl Oncol
Reference: T cellIEDB
9 publications
- A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy.
2025 · Nat Biotechnol · RCR 19.4 · 68 citations - Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells.
2013 · Sci Transl Med · RCR 14 · 592 citations - Tuning T cell receptor sensitivity through catch bond engineering.
2022 · Science · RCR 7.6 · 128 citations - T-Scan: A Genome-wide Method for the Systematic Discovery of T Cell Epitopes.
2019 · Cell · RCR 5.8 · 198 citations - A library of cancer testis specific T cell receptors for T cell receptor gene therapy.
2023 · Mol Ther Oncolytics · RCR 0.7 · 14 citations
Show 4 more
- Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma.
2020 · Elife · RCR 0.6 · 17 citations - Identification of novel MAGE-A6- and MAGE-A12-derived HLA-A24-restricted cytotoxic T lymphocyte epitopes using an in silico peptide-docking assay.
2012 · Cancer Immunol Immunother · RCR 0.4 · 16 citations - Broadening the repertoire of melanoma-associated T-cell epitopes.
2015 · Cancer Immunol Immunother · RCR 0.2 · 9 citations - Exceptional tumor-free survival of a patient with metastatic intrahepatic cholangiocarcinoma after surgery and personalized peptide vaccination: revisiting a striking case.
2025 · J Immunother Cancer
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD missense Z
- -4.36
- DepMap mean gene effect
- -0.07
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of MAGEA6 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads MAGEA6 as an antibody target. Whether an autoantibody or antibody against MAGEA6 could matter depends on whether native MAGEA6 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
MAGEA6 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label MAGEA6 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...